Drug intelligence / Profile preview

GB-AOS9

Development stage: Preclinical
Lead developer: GlycosBio
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Topical

Overview

GB-AOS9 is a preclinical-stage therapeutic candidate being developed by GlycosBio for the treatment of periodontal disease. The drug utilizes GlycosBio's proprietary Activated Oil System (AOS), which is a lipid-based delivery and therapeutic platform. AOS is designed to address oral health issues by potentially modulating the oral microbiome or reducing inflammation associated with periodontitis. As of 2024, the program remains in the preclinical phase of development.

Beyond the preview

Go deeper on GB-AOS9.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GB-AOS9.

Explore the full profile